The specter of generic challenges has long loomed around copyright’s iconic drug, Sildenafil, sparking questions about the outlook of similar here pharmaceutical stakes. While initial years saw substantial returns, the intellectual property expiration has opened the door for discounted alternatives, likely reducing earnings and posing a real risk